Lantern Pharma Wins FDA Orphan Drug Status for LP-284 Cancer Therapy | NewsOut

Jan 20, 2026

Biotech and healthcare investors: Lantern Pharma (NASDAQ: LTRN) has received FDA orphan drug designation for its cancer therapy LP-284 for the treatment of soft tissue sarcoma, a rare and aggressive cancer with limited treatment options.

Reporting from News Out, Ana Berry explains that the designation provides key benefits, including potential tax credits, development incentives, and seven years of market exclusivity if approved. This marks the third orphan designation for LP-284 and the sixth across Lantern’s pipeline, highlighting growing momentum behind the company’s AI-driven precision oncology strategy.

#LanternPharma
#LTRN
#OrphanDrug
#CancerTherapy
#PrecisionOncology
#BiotechNews
#FDAApproval
#RareDisease
#OncologyResearch
#AIinBiotech
#NASDAQ
#AnaBerry
#NewsOut